Population Health Partners
Andrew Friedman, PharmD, currently serves as the Executive Vice President of Regulatory & Development at Validae Health, a part of Population Health Partners, since April 2021. Previously, Friedman held significant roles in regulatory affairs at prominent pharmaceutical companies including Novartis as SVP Regulatory, The Medicines Company as Sr. Vice President and Head of Regulatory Affairs, Bristol-Myers Squibb as Executive Director of Global Regulatory Strategy, and Roche Pharmaceuticals as Global Head of CNS Drug Regulatory Affairs. Additional experience includes regulatory positions at Forest Laboratories and Merck. Academic credentials include a Doctor of Pharmacy from Shenandoah University and bachelor's degrees in Pharmacy from Long Island University and Communications from Brooklyn College.
This person is not in any teams
This person is not in any offices
Population Health Partners
Population Health Partners is an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations. They bring together investment capital with industry-leading capabilities and technology, delivering unprecedented product development efficiency and disruptive business models, with the goal of creating alpha for investors who want to back breakthroughs in the world’s leading therapeutics of the future.